Talphera (NASDAQ:TLPH) & Acusphere (OTCMKTS:ACUS) Financial Comparison

Talphera (NASDAQ:TLPH) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Profitability

This table compares Talphera and Acusphere’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Acusphere	N/A	N/A	N/A

Institutional & Insider Ownership

37.7% of Talphera shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 4.6% of Acusphere shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Talphera and Acusphere, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1	0	1	0	2.00
Acusphere	0	0	0	0	0.00

Talphera presently has a consensus price target of $3.00, indicating a potential upside of 264.08%. Given Talphera’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Talphera is more favorable than Acusphere.

Earnings & Valuation

This table compares Talphera and Acusphere”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30,000.00	1,425.52	-$14.29 million	($0.31)	-2.66
Acusphere	N/A	N/A	N/A	N/A	N/A

Acusphere has lower revenue, but higher earnings than Talphera.

Summary

Talphera beats Acusphere on 5 of the 8 factors compared between the two stocks.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.